Opinions
- Bob Mason
The UK becomes the first nation to approve a COVID-19 vaccine and with an efficacy rate of 95%, an end to the pandemic may be in sight.
- Bob Mason
Time is running out and yet both sides stand firm on the remaining hurdles. The markets and the Pound continue to reflect optimism, however.
- Bob Mason
Moderna Inc. submits its EUA to the FDA, with both Pfizer Inc. and Moderna Inc. also submitting requests to the EMA.
- Bob Mason
AstraZeneca last week announced plans to launch a new global trial. Without the AstraZeneca vaccine, however, many nations will be without…
- Vladimir Zernov
There is some rotation from tech stocks into cyclical stocks.
- Bob Mason
As more details emerge from AstraZeneca’s clinical trials, the door may be ajar for another U.S pharma to make a move.
- Bob Mason
As Brexit talks get set to resume, Boris may be feeling hot under the collar. A message from Biden and a warning from the EU. Compromise or else…
- Bob Mason
Face to face talks are set to resume with Barnier coming out of self-isolation. The two sides at odds, however, with time running out.
- Bob Mason
AstraZeneca and the University of Oxford fail to impress the markets with phase 3 trial results. Logistics and production could favor their vaccine, however.
- Bob Mason
Pfizer Inc. and BioNTech submit a EUA. Moderna Inc. and AstraZeneca need to catch up…
- Bob Mason
Brexit talks hit pause as EU negotiators self-isolate. With the transition period ending in just over a month, is an extension around the corner?
- Bob Mason
Pfizer Inc. addresses safety concerns and virus efficacy amongst the elderly. Is it enough for the FDA to approve and for manufacturing to commence?
- Bob Mason
The proverbial can continues to get kicked down the road. Brexit talks continue and the EU Summit on Thursday may not be the end of it.
- Bob Mason
Moderna Inc. delivers the world with yet more hope of an end to the global pandemic. More data is going to be needed, however.
- Bob Mason
More clinical trial results are due out from Pharmas in the coming weeks. Safety, duration, and manufacturing data from Pfizer will also be in focus.
- Bob Mason
Anarchy or an orderly handover? There are reasons why the markets should worry…
- Bob Mason
It’s the final countdown. EU – UK negotiators have until the 19th November EU Summit to wrap things up.
- Bob Mason
Boris Johnson may rue allowing talks to extend beyond October. A Biden victory will put the cat amongst the pigeons…
- Bob Mason
The 2nd wave of the COVID-19 pandemic could have a far more severe economic impact. Can Asia avoid the meltdown?
- Bob Mason
There’s a week to go before the U.S Presidential Election. The swing states are back in focus and it’s not a sure thing for Joe Biden…
